Meeting of the Permanent Commission

The Permanent Commission of the Competition Council held its meeting, via videoconference, on Thursday, February 18, 2021 at 9:00 a.m., under the chairmanship of Mr. Driss Guerraoui, President of the Council.

At the beginning of its work, the Permanent Commission approved the minutes of its meeting held on February 11, 2021.

During this meeting, and noting the absence of impacts on competition in the relevant national markets, the Permanent Commission made decisions to authorize the following four economic concentration operations:

• • • • • The joint control of the Tanger Tech Development Company (SATT) through the acquisition of 20% of the Tanger Med Special Agency (TMSA) and 35% of the capital and voting rights by Beijing Zhonglu Urban Development Company Ltd;
        • The direct exclusive control of Cheplapharm Arzneimittel Gmbh through the acquisition of assets of Sanofi related to the production and marketing of Sectral and Corvasal medicines used in the treatment of heart diseases;
        • The exclusive control through the acquisition of Zephyr German BidCo Gmbh of all the share capital and voting rights of FlenderGmbh;
        • The direct exclusive control of the Akdital holding group through the acquisition of all the shares of the capital of Gimes da vinci sarlu, which operates the De vinci Clinic”.